Taysha Gene Therapies, Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. Although the request references 2021 Q4, this filing reports full-year results; it does not provide a clear standalone Q4 financial summary. The filing was signed March 31, 2022. Taysha is a clinical-stage gene therapy company focused on AAV-based treatments for monogenic central nervous system diseases.
Financial performance and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $131.9 million | $31.9 million |
| General and administrative expense | $41.3 million | $11.1 million |
| Total operating expenses / operating loss | $173.3 million | $43.0 million |
| Net loss | $174.5 million | $60.0 million |
| Net loss per share, basic and diluted | $4.64 | $3.40 |
| Net cash used in operating activities | $117.0 million | $30.7 million |
| Net cash used in investing activities | $21.6 million | $9.1 million |
| Net cash provided by financing activities | $39.1 million | $291.1 million |
At year-end, cash and cash equivalents were $149.1 million, restricted cash was $2.6 million, and total assets were $214.0 million. Total liabilities were $118.6 million; stockholders’ equity was $95.4 million. The company had no product revenue, so revenue-based margins are not meaningful. It reported no off-balance-sheet arrangements.
Outstanding term-loan principal was $40.0 million, reported net of debt discount as $37.2 million. The loan bears interest at the greater of prime plus 3.75% or 7.00%; interest-only payments run through August 2024, with maturity on August 1, 2026. A 7.5% exit fee is payable upon full repayment. The debt is secured by company assets other than intellectual property, which is subject to a negative pledge. Taysha reported covenant compliance at year-end.
Changes versus the prior year
- Net loss increased to $174.5 million from $60.0 million, while operating cash use rose to $117.0 million from $30.7 million.
- R&D expense increased by $100.0 million, principally due to manufacturing and raw-material costs, employee compensation, and third-party development and clinical consulting.
- G&A expense increased by $30.2 million, reflecting higher compensation and professional fees.
- Cash and cash equivalents declined from $251.3 million to $149.1 million. Financing proceeds were much lower than in 2020, when the company completed its IPO and preferred-stock financings.
- Property, plant and equipment rose to $50.6 million from $0.3 million, mainly reflecting construction and build-out of the Durham manufacturing facility.
Outlook, pipeline and notable items
- Funding outlook: Management estimated that year-end cash plus full access to the term-loan facility would fund operations into Q4 2023. This estimate incorporates the March 2022 restructuring and depends on assumptions that may prove incorrect. Additional capital will be needed to advance development and manufacturing.
- Post-year-end prioritization: In March 2022, Taysha prioritized GAN and Rett syndrome, planned small proof-of-concept studies for CLN1 and SLC13A5, and continued CLN7 development with partners using the first-generation construct. Other R&D activities were paused. Headcount was reduced approximately 35%; estimated severance and termination costs were $1.4 million, expected to be recorded in Q1 2022.
- Clinical programs: TSHA-120 for GAN had 14 patients dosed in an NIH Phase 1/2 trial; the company reported encouraging functional and safety data, including long-term follow-up, but results remain from a small, open-label study. TSHA-102 for Rett received Health Canada CTA clearance in March 2022, with preliminary clinical data expected by year-end 2022. The company planned to initiate TSHA-105 clinical development in 2022. CLN1 and CLN7 programs were in clinical development with partners.
- Paused program and unusual event: Development and the clinical trial of TSHA-101 for GM2 were paused as part of the operating-efficiency initiative. Three patients had been dosed. One participant died after pneumonia, pleural effusion and a hospital-acquired MRSA infection; the principal investigator and independent safety board determined the death was not related to study drug. The company said preliminary biomarker findings in treated patients were encouraging.
- Manufacturing and commitments: Durham facility construction remained underway. Year-end commitments included approximately $12.0 million for facility build-out and $8.1 million in cancellable CRO purchase obligations. Aggregate disclosed lease commitments were $52.2 million.
- Other funding capacity: The company had an effective shelf registration and an at-the-market sales agreement permitting up to $150 million of common-stock sales; no shares had been sold under the agreement as of December 31, 2021. Access to later loan tranches is conditional, including on clinical-program requirements and lender approval.
- Key risks: Taysha has no approved products or product-sale revenue, has a limited operating history, and expects continued losses. Development, regulatory approval, patient enrollment, AAV manufacturing scale-up, reliance on UT Southwestern and other third parties, intellectual-property rights, and future financing are material uncertainties. COVID-19 could disrupt trials, supply, operations or capital access, although FY 2021 results were not materially affected.
The independent auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation because Taysha qualified as an emerging growth company.
Investor verification priorities
- Confirm current cash, monthly burn, and whether the Q4 2023 runway estimate remains achievable after the pipeline changes and facility spending.
- Check the conditions and availability of remaining loan tranches, interest and exit-fee obligations, and any subsequent ATM equity issuance or dilution.
- Review updated clinical data, trial status and regulatory feedback for GAN and Rett, including the basis and limitations of comparisons with natural history.
- Track the consequences of paused programs, the 35% workforce reduction, severance costs, and the company’s commitments to partners and licensors.
- Assess Durham facility completion, commercial-scale manufacturing readiness, and associated lease and build-out obligations.